Seeking Molecular Markers To Identify Breast Cancer Patients Who Would Benefit Most F

tD33NAt

Active member
Mar 24, 2008
12,519
0
36
A new analysis may help doctors identify breast cancer patients who will benefit from treatment with the immune suppressant drug everolimus, say French researchers at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium. Everolimus is currently used as an immunosuppressant to prevent patients rejecting transplanted organs and in the treatment of renal cell cancer. Research is also being conducted into the drug's use in other cancers, including breast cancer...
CfNb5Ow1VdY


More...
 
Back
Top